Buy Like Buffett
Watchlist

Flagship explainer

How BioXcel Therapeutics, Inc. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$642000 · 100%Cost of revenue$164000 · 26%Gross profit$478000 · 74%Operating income−$50.5M · −7860%Income before tax−$69.9M · −10887%Income tax$0 · 0%Net income−$69.9M · −10887%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$642000100%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-036214 · filed Mar 27, 2026
Cost of revenue$16400026%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-036214 · filed Mar 27, 2026
$47800074%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-036214 · filed Mar 27, 2026
−$50.5M−7860%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-036214 · filed Mar 27, 2026
Income before tax−$69.9M−10887%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-036214 · filed Mar 27, 2026
Income tax$00%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-036214 · filed Mar 27, 2026
−$69.9M−10887%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-036214 · filed Mar 27, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-036214 · filed Mar 27, 2026
· event Dec 31, 2025 · retrieved Sep 19, 2026 · annual-row source set
Embed this chart

View the full BioXcel Therapeutics, Inc. analysis at Buy Like Buffett